Patents by Inventor Ling Qiu
Ling Qiu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9676802Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: Q-G-A-L-B—Z—W??(I), which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: April 16, 2014Date of Patent: June 13, 2017Assignee: ENANTA PHARMACEUTICALS, INC.Inventors: Yao-Ling Qiu, Hui Cao, Xiaowen Peng, Zhigang Chen, Yat Sun Or
-
Patent number: 9675632Abstract: The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: August 26, 2015Date of Patent: June 13, 2017Assignee: ENANTA PHARMACEUTICALS, INC.Inventors: Yao-Ling Qiu, Xiaowen Peng, Xuri Gao, Hui Cao, Yat Sun Or
-
Publication number: 20170114046Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: October 31, 2016Publication date: April 27, 2017Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Lu Ying, Yat Sun Or
-
Publication number: 20170022150Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A1-Y-A2-Z-L-R??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: July 21, 2016Publication date: January 26, 2017Inventors: Yao-Ling Qiu, Wei Li, Hui Cao, Meizhong Jin, Jorden Kass, Xuri Gao, Xiaowen Peng, Yat Sun Or
-
Publication number: 20170026984Abstract: An embodiment method includes obtaining information about a serving node and information about a coordinating node of an edge user, performing coordinated scheduling on the edge user according to the information about the serving node and the information about the coordinating node, determining whether the serving node and the coordinating node can simultaneously schedule the edge user. In response to a determination that the serving node and the coordinating node can simultaneously schedule the edge user, the method further includes instructing the serving node and the coordinating node to allocate a same code channel resource to send data to the edge user.Type: ApplicationFiled: October 7, 2016Publication date: January 26, 2017Inventors: Yinke Shi, Libo Wang, Ling Qiu, Zongjie Wang, Peng Zhang
-
Publication number: 20170014408Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: July 13, 2016Publication date: January 19, 2017Inventors: Yao-Ling Qiu, Hui Cao, Wei Li, Xiaowen Peng, Meizhong Jin, Jorden Kass, Xuri Gao, Yat Sun Or
-
Publication number: 20160332996Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: May 12, 2016Publication date: November 17, 2016Inventors: Yao-Ling Qiu, Wei Li, Hui Cao, Meizhong Jin, Xuri Gao, Xiaowen Peng, Jorden Kass, Yat Sun Or
-
Publication number: 20160309458Abstract: The present invention provides a method, an apparatus, and a system for allocating an uplink resource, and a macro base station. A macro base station classifies user equipment into a first user equipment group or a second user equipment group according to a measurement report reported by the user equipment, and allocates, based on a proportion of a quantity of user equipments in the first user equipment group to a quantity of user equipments in the second user equipment group, uplink data transmission subframes to the user equipments in the first user equipment group and the user equipments in the second user equipment group. In this way, the uplink user equipment, which produces interference, of the macro base station does not occupy a resource of uplink user equipment of a micro base station, thereby improving overall performance of the uplink user equipment of the micro base station.Type: ApplicationFiled: June 24, 2016Publication date: October 20, 2016Applicant: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Zongjie WANG, Peng ZHANG, Zengxin WANG, Ling QIU
-
Publication number: 20160302221Abstract: This application relates to a schedule weight adjustment method applied to a HSDPA Het-Net system. The method includes: acquiring, by a first base station, a first CQI, which is on a first carrier, of user equipment in a LPN expansion area, and a first TBS, which is on a second carrier, of the user equipment, where the first carrier is used to communicate with the first base station, the second carrier is used to communicate with a second base station, and a cell offset is set on the first carrier or the second carrier; determining, according to the first CQI and the first TBS, whether a service rate obtained from the second base station by the user equipment is greater than a service rate obtained from the first base station; and adjusting a schedule weight of the user equipment in the first base station according to the determining result.Type: ApplicationFiled: June 23, 2016Publication date: October 13, 2016Applicant: HUAWEI TECHNOLOGIES CO., LTD.Inventors: Zongjie WANG, Peng Zhang, Yi Huang, Jingxing Chu, Ling Qiu
-
Publication number: 20160289212Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R1??(I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: April 1, 2016Publication date: October 6, 2016Inventors: Yao-Ling Qiu, Hui Cao, Wei Li, Jorden Kass, Xuri Gao, Xiaowen Peng, Meizhong Jin, Yat Sun Or
-
Publication number: 20160222034Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: January 27, 2016Publication date: August 4, 2016Inventors: Yao-Ling Qiu, Hui Cao, Xiaowen Peng, Xuri Gao, Yat Sun Or, Zachary Kevin Sweeney
-
Publication number: 20160159843Abstract: The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: December 4, 2015Publication date: June 9, 2016Inventors: Yao-Ling Qiu, Hui Cao, Wei Li, Xuri Gao, Xiaowen Peng, Jorden Kass, Yat Sun Or
-
Patent number: 9288802Abstract: The present invention discloses a method, device, and system for sending and receiving control channel information. When a base station schedules a first relay, the base station selects a second relay according to an optimal precoding code book selected by the first relay. An optimal precoding code book selected by the second relay is orthogonal to the optimal precoding code book selected by the first relay. Control channel information of the first relay and control channel information of the second relay his encapsulated into a high speed downlink shared control channel HS-SCCH, and scrambling the HS-SCCH. The scrambled HS-SCCH is sent to the first relay and the second relay.Type: GrantFiled: May 23, 2014Date of Patent: March 15, 2016Assignee: Huawei Technologies Co., Ltd.Inventors: Chongfa Wang, Ling Qiu, Zongjie Wang
-
Publication number: 20160058783Abstract: The present invention discloses compounds of formula (I), or a pharmaceutically acceptable salt thereof: which inhibit, preventing or treating abnormal cellular proliferation and/or a viral infection, particularly by HIV, HCV or HBV. Consequently, the compounds of the present invention interfere with the replication cycle of a virus and are also useful as antiviral agents, or interfere with host cellular biochemical process and are also useful as antiproliferative agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from viral infection and/or cell proliferation. The invention also relates to methods of treating a viral infection and/or cell proliferation in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: ApplicationFiled: August 26, 2015Publication date: March 3, 2016Inventors: Yao-Ling Qiu, Xiaowen Peng, Xuri Gao, Hui Cao, Yat Sun Or
-
Patent number: 9156818Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with compounds of Formula (I).Type: GrantFiled: September 10, 2010Date of Patent: October 13, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Xiaowen Peng, Ce Wang, Lu Ying, Yao-Ling Qiu
-
Publication number: 20150259212Abstract: The present invention relates to graphene-based foam, the graphene-based foam having a structure defined by a three-dimensional network of interconnected and ordered open cells, the open cells being defined by cell walls, the cell walls (i) being formed of graphene sheets, partially reduced graphene oxide sheets, reduced graphene oxide sheets, or a combination thereof, and (ii) having a thickness defined by the thickness of a plurality of graphene sheets, partially reduced graphene oxide sheets, reduced graphene oxide sheets, or a combination thereof.Type: ApplicationFiled: August 23, 2013Publication date: September 17, 2015Applicant: MONASH UNIVERSITYInventors: Dan Li, Ling Qiu
-
Patent number: 9127021Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: April 8, 2011Date of Patent: September 8, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yao-Ling Qiu, Ce Wang, Xiaowen Peng, Yat Sun Or
-
Patent number: 9085599Abstract: The present invention relates to 2?-allene-substituted nucleoside derivatives of the general formula (I): As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related ?-D and ?-L-nucleoside derivatives.Type: GrantFiled: March 16, 2012Date of Patent: July 21, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Jun Ma, Guoqiang Wang, In Jong Kim, Jiang Long, Yao-Ling Qiu
-
Patent number: 9060971Abstract: The present invention relates to pharmaceutical agents administered to a subject either in combination or in series for the treatment of a flaviviridae viral infection, for example, hepatitis C virus (HCV), wherein treatment comprises administering a compound effective to inhibit the function of the HCV NS5A protein and an additional compound or combinations of compounds having anti-HCV activity.Type: GrantFiled: August 5, 2010Date of Patent: June 23, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yat Sun Or, Christopher M. Owens, Bradley B. Brasher, Yao-Ling Qiu, Lijuan Jiang
-
Patent number: 9000020Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.Type: GrantFiled: October 30, 2012Date of Patent: April 7, 2015Assignee: Enanta Pharmaceuticals, Inc.Inventors: Yao-Ling Qiu, Ce Wang, Lu Ying, Xiaowen Peng, Yat Sun Or